Effects of Bile Acids on GLP-1 Secretion After Roux-en-Y Gastric Bypass
NCT ID: NCT02340247
Last Updated: 2016-06-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
11 participants
INTERVENTIONAL
2014-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass
NCT02952963
Gut Hormones as Mediators of Different Weight Loss Responses After Roux-en-Y Gastric Bypass
NCT02374632
Effects of Gastric Bypass Surgery on Bile Acid Homeostasis
NCT03475849
Effect of Gastric Bypass Surgery on Pancreatic Islets and Incretin Function
NCT01559779
Influence of Gut Hormones on Food Intake After Roux-en-Y Gastric Bypass Surgery
NCT02336659
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
CROSSOVER
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
150mL water
Water
Ursodeoxycholic acid
Ursodeoxycholic acid (750mg) dissolved in 150mL water
Ursodeoxycholic Acid
Chenodeoxycholic acid
Chenodeoxycholic acid (1250mg) dissolved in 150mL water
Chenodeoxycholic Acid
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Water
Ursodeoxycholic Acid
Chenodeoxycholic Acid
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Fasting plasma glucose \< 7.0mM, HbA1c \< 48mmol/mol 3 months after RYGB.
Exclusion Criteria
* Dysregulated hypothyroidism, use of antithyroid treatment.
* Late diabetic complications as retinopathy, renal insufficiency, neuropathy or previous pancreatitis.
* Complications to RYGB: Documented reactive hypoglycaemia, severe dumping (vomiting, diarrhea, severe abdominal pain after food intake).
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Copenhagen
OTHER
Hvidovre University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Maria Saur Svane
MD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hvidovre University Hospital
Hvidovre, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SN-GALDE-14
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.